NASDAQ:TLIS Talis Biomedical (TLIS) Stock Price, News & Analysis $1.50 0.00 (0.00%) As of 08/1/2025 Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Talis Biomedical Stock (NASDAQ:TLIS) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Talis Biomedical alerts:Sign Up Key Stats Today's Range$1.50▼$1.5050-Day Range$1.25▼$1.7552-Week Range$1.04▼$9.35Volume2 shsAverage Volume2,458 shsMarket Capitalization$2.73 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Talis Biomedical Corporation operates as a molecular diagnostic company, focusing on developing medical devices for infectious diseases and other conditions at the point of care in the United States. Talis Biomedical Corporation was incorporated in 2013 and is headquartered in Chicago, Illinois. Read More Receive TLIS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Talis Biomedical and its competitors with MarketBeat's FREE daily newsletter. Email Address TLIS Stock News HeadlinesBaker Bros. Advisors LP's Strategic Acquisition in Talis Biomedical CorpOctober 10, 2024 | finance.yahoo.comTalis Biomedical Corp Ordinary SharesSeptember 17, 2024 | morningstar.comMA new rule goes live in July — and the banks are quietly crushing itA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Street and the Big Banks… It gives them the green light to treat a certain tangible asset as equivalent to cold, hard cash. Not stocks. Not real estate. And definitely not the U.S. dollar. We're talking about something they don't want you to notice — because the fewer people who act on this, the better it is for them.August 3 at 2:00 AM | American Alternative (Ad)Talis Biomedical Shares Fall on Bankruptcy Filing, Delisting NoticeAugust 24, 2024 | marketwatch.comTLIS Stock Earnings: Talis Biomedical Reported Results for Q2 2024August 19, 2024 | investorplace.comTalis Biomedical Shares Tumble Premarket as Company Mulls BankruptcyAugust 7, 2024 | marketwatch.comWhy Talis Biomedical (TLIS) Stock Is Getting Obliterated TodayAugust 7, 2024 | benzinga.comWhy Is Talis Biomedical (TLIS) Stock Down 52% Today?August 7, 2024 | investorplace.comSee More Headlines TLIS Stock Analysis - Frequently Asked Questions How have TLIS shares performed this year? Talis Biomedical's stock was trading at $1.7590 at the beginning of the year. Since then, TLIS shares have decreased by 14.7% and is now trading at $1.50. How were Talis Biomedical's earnings last quarter? Talis Biomedical Co. (NASDAQ:TLIS) announced its quarterly earnings data on Tuesday, March, 15th. The company reported ($18.90) earnings per share (EPS) for the quarter, beating the consensus estimate of ($19.20) by $0.30. When did Talis Biomedical's stock split? Talis Biomedical's stock reverse split before market open on Thursday, July 6th 2023.The 1-15 reverse split was announced on Thursday, July 6th 2023. The number of shares owned by shareholders was adjusted after the market closes on Thursday, July 6th 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. When did Talis Biomedical IPO? Talis Biomedical (TLIS) raised $150 million in an initial public offering (IPO) on Friday, February 12th 2021. The company issued 10,000,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, BofA Securities and Piper Sandler served as the underwriters for the IPO and BTIG was co-manager. How do I buy shares of Talis Biomedical? Shares of TLIS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Talis Biomedical own? Based on aggregate information from My MarketBeat watchlists, some other companies that Talis Biomedical investors own include Bloom Energy (BE), SoFi Technologies (SOFI), Athenex (ATNX), Alkaline Water (WTER), Milestone Scientific (MLSS), TherapeuticsMD (TXMD) and Affirm (AFRM). Company Calendar Last Earnings3/15/2022Today8/03/2025Next Earnings (Estimated)8/18/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Analytical instruments Sub-IndustryMeasuring And Control Equipment Current SymbolNASDAQ:TLIS CIK1584751 Webtalis.bio Phone650-433-3000FaxN/AEmployees260Year FoundedN/AProfitability EPS (Trailing Twelve Months)($28.02) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$62.01 million Net MarginsN/A Pretax Margin-12,506.37% Return on Equity-79.74% Return on Assets-57.16% Debt Debt-to-Equity RatioN/A Current Ratio7.76 Quick Ratio7.76 Sales & Book Value Annual Sales$300 thousand Price / Sales9.12 Cash FlowN/A Price / Cash FlowN/A Book Value$37.95 per share Price / Book0.04Miscellaneous Outstanding Shares1,823,000Free Float984,000Market Cap$2.73 million OptionableNo Data Beta1.29 Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report This page (NASDAQ:TLIS) was last updated on 8/3/2025 by MarketBeat.com Staff From Our PartnersMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredEx-Hedge Fund Manager Uncovers $100 Trillion Land ShiftTrump's Radical New Plan Could Enrich Thousands This isn't a campaign stunt. It's a $100 trillion move to u...Stansberry Research | SponsoredI’d rather trade news like this than gamble on hypeReal traders are watching Nvidia’s next move—after U.S. approval to resume chip sales to China. This reversal ...Timothy Sykes | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredInvestigating the Most Controversial Stock on EarthTesla’s wild price swings may not be random after all. Hedge fund veteran Larry Benedict has uncovered a st...Brownstone Research | SponsoredThis New Rule Could Change EverythingA major change is quietly going into effect this July — and Wall Street is already positioning for it. Big ...American Alternative | SponsoredSell these "safe" blue chips immediatelyInvesting Legend Hints the End May be Near for These 3 Iconic Stocks One company to replace Amazon… another...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Talis Biomedical Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Talis Biomedical With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.